Drug Trial Radar · NCT06216158
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
411
Planned (sponsor's estimate)
Start
Apr 5, 2024
Primary completion
Dec 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- University of Heidelberg Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- KKS Netzwerk; Wuerzburg University Hospital; Sanofi; Bristol-Myers Squibb
- First posted
- Jan 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to compare a maintenance therapy consisting of iberdomide and isatuximab with an iberdomide-only regimen. The trial is the subsequent maintenance therapy to GMMG-HD8/DSMM XIX trial for patients with newly-diagnosed multiple myeloma. Patients with newly-diagnosed multiple myeloma who underwent a similar quadruplet induction/consolidation therapy regimen followed by at least one ASCT can also be recruited. The main question it aims to answer is: • Will the addition of isatuximab lead to decreased amounts of measurable myeloma cells in the bone marrow after two years?
Conditions
- Multiple Myeloma
Interventions
IberdomideDrug
Iberdomide p.o. (0.75 mg, day 1-21 of each 29-days cycle)
IsatuximabDrug
Isatuximab s.c. (1400 mg, cycle 1: day 1, 8, 15, 22; cycles 2-3: day 1 and 15; from C4: day 1)
DexamethasoneDrug
Dexamethasone p.o. or i.v. (20 mg, cycle 1 only: day 1, 8, 15, 22)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Demonstration of superiority of iberdomide plus isatuximab compared to iberdomide with respect to bone marrow minimal residual disease (MRD).Time frame: 24 months after start of maintenance therapy
Locations
69 sites in 2 countries. Site status is shown where the registry gives one.
Universitätsklinikum Krems an der Donau
Krems, Austria
Ordensklinikum Linz Elisabethinen
Linz, Austria
Landeskrankenhaus Salzburg, Universitätsklinik für Innere Medizin III
Salzburg, Austria
Klinik Ottakring Wien
Vienna, Austria
Klinikum Wels-Grieskirchen GmbH
Wels, Austria
Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation
Aachen, Germany
Universitätsklinikum
Augsburg, Germany
Helios Klinikum Bad Saarow
Bad Saarow, Germany
Charité, III. Medizinische Abteilung
Berlin, Germany
Vivantes Klinikum Neukölln, Klinik für Hämatologie und Onkologie
Berlin, Germany
Helios Klinikum Berlin-Buch
Berlin, Germany
Onkologische Schwerpunktpraxis Bielefeld
Bielefeld, Germany
Evangelisches Klinikum Bethel
Bielefeld, Germany
Johanniter Krankenhaus
Bonn, Germany
Universitätsklinikum Bonn
Bonn, Germany
Städtisches Klinikum
Braunschweig, Germany
Klinikum Chemnitz
Chemnitz, Germany
Carl-Thiem-Klinikum Cottbus gGmbH, 2. Medizinische Klinik
Cottbus, Germany
Klinikum Darmstadt GmbH, Medizinische Klinik V
Darmstadt, Germany
Städtisches Klinikum
Dessau, Germany
St. Johannes Hospital Dortmund
Dortmund, Germany
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Germany
Universitätsklinikum Düsseldorf
Düsseldorf, Germany
Marien Hospital Düsseldorf GmbH, Klinik für Onkologie, Hämatalogie und Palliativmedizin
Düsseldorf, Germany
St. Antonius-Hospital
Eschweiler, Germany
KEM I Evang. Kliniken Essen-Mitte gGmbH, Evangelisches Krankenhaus Essen-Werden gGmbH, Klinik für Hämatologie, Onkologie und Stammzelltransplantation
Essen, Germany
Malteser Krankenhaus
Flensburg, Germany
Universitätsklinikum Frankfurt
Frankfurt, Germany
Centrum für Hämatologie und Onkologie Bethanien
Frankfurt am Main, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Universitätsmedizin Greifswald
Greifswald, Germany
Katholisches Krankenhaus Hagen
Hagen, Germany
Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie
Hamburg, Germany
Asklepios Klinik Altona
Hamburg, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Onkologische Schwerpunktpraxis
Heidelberg, Germany
Universitätsklinikum Heidelberg, Medizinische Klinik V
Heidelberg, Germany
SLK Kliniken Heilbronn, Medizinische Klinik III
Heilbronn, Germany
Universitätsklinikum des Saarlandes, Klinik für Innere Medizin 1
Homburg, Germany
Klinikum der Friedrich-Schiller-Universität Jena, Klinik für Innere Medizin II, Abteilung Hämatologie und internistische Onkologie
Jena, Germany
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.